Publisher Summary Osteogenesis imperfecta (OI) or “brittle bone disease” is characterized
by reduced skeletal mass and bone fragility. OI has served as the paradigm for heritable …

Nitrogen-containing bisphosphonates (nBPs) are bone-specific agents that inhibit farnesyl
diphosphate synthase. nBPs' strong affinity for bone, and not for other tissues, makes them …

Objectives: Osteogenesis imperfecta (OI) is a rare hereditary disease leading to bone
fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been …

Bisphosphonates have been widely administered to children with OI based on observational
trials. A randomized controlled trial of q3m intravenous pamidronate in children with types III …

Recent medical and surgical advances have allowed improved safety, function and comfort
in treating children with osteogenesis imperfecta. The selection of surgical techniques is …

Results in small patient series suggest that cyclical intravenous treatment with pamidronate
can lead to reshaping of compressed vertebral bodies in children and adolescents with …

Abstract Background/Aims: To systematically assess contemporary knowledge regarding the
effectiveness and safety of bisphosphonates (BPs) in children with osteogenesis imperfecta …

The Task Force focusing on the use of dual energy X-ray absorptiometry (DXA) in children
and adolescents with diseases that may affect the skeleton reviewed over 300 articles to …

Background: Intravenous disodium pamidronate has become an established treatment in
osteogenesis imperfecta (OI). Another bisphosphonate, zoledronic acid, has been indicated …

Abstract A 3‐year, randomized, double‐blind, placebo‐controlled trial evaluated the effect of
oral alendronate on the BMD of 64 adult patients with osteogenesis imperfecta. The mean …